Actively Recruiting
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity
Led by Wake Forest University Health Sciences · Updated on 2026-03-20
70
Participants Needed
1
Research Sites
402 weeks
Total Duration
On this page
Sponsors
W
Wake Forest University Health Sciences
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed hematologic malignancy and potentially other cancers.
CONDITIONS
Official Title
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with suspected or confirmed hematologic malignancy undergoing a bone marrow biopsy as part of their care.
- Ability to understand and willingness to sign an IRB approved informed consent document.
You will not qualify if you...
- None specified.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157
Actively Recruiting
Research Team
S
Study Coordinator
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here